Study S002526

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

ClinicalTrials.gov record

Registration

Registration: NCT07400653
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 1078
Start: 2026-02-24
Primary completion: 2027-10-12
Lead sponsor: Pfizer
Conditions: Obesity; Overweight and/or Obesity; Overweight; Diabetes, Type 2; Type 2 Diabetes
Interventions: DRUG:PF-08653944; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:MET097-25-302; REGISTRY:2025-523975-48-00; OTHER:VESPER-5; NIH:2025

Registered primary outcomes

Percent Change from baseline in body weight [Baseline, Week 64]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.